Oncolys BioPharma Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Oncolys BioPharma Inc. - overview
Established
2004
Location
Tokyo, Tokyo, Japan
Primary Industry
Pharmaceuticals
About
Oncolys BioPharma Inc. is a biopharmaceutical company engaged in the research and development of innovative therapeutics, focusing primarily on oncology and infectious diseases through its proprietary technologies. Oncolys BioPharma Inc. was founded in 2004 and is headquartered in Tokyo, Japan.
The company specializes in the development of therapeutic solutions for cancer and viral infections. In December 2013, Oncolys completed an IPO, raising JPY 6600 million by issuing 2. 55 million shares at a price of JPY 2600 each, marking a significant milestone in its funding journey. The company has participated in five total deals since its inception.
Oncolys BioPharma Inc. specializes in the research and development of innovative therapeutics, focusing on oncology and infectious diseases. The company’s core offerings include investigational cancer therapies targeting specific tumor markers to enhance treatment efficacy and minimize side effects. Its technology aims to provide personalized treatment protocols for diverse patient populations across North America, Europe, and parts of Asia.
Oncolys also collaborates with healthcare providers and pharmaceutical companies to expand its reach and facilitate product development and distribution. In the most recent year, 2023, Oncolys BioPharma Inc. reported revenues of JPY 449,646. 4, accompanied by an EBITDA of -JPY 13,745,686.
6. The company generates revenue primarily through partnerships and collaborations, involving milestone payments, royalties, and revenue-sharing agreements related to its drug pipeline. Oncolys BioPharma Inc. is focusing on the development of new cancer and infectious disease therapies, with plans to launch several investigational products in the upcoming years.
The company aims to expand its presence in North America and Europe by the end of 2025. The funds raised through the IPO in December 2013 will be utilized to support these initiatives, enhancing its capabilities in clinical development and market entry.
Current Investors
Ant Capital Partners, Nomura Research Institute, Ltd., Mitsui Sumitomo Insurance Venture Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Epidemiology, Pharmaceutical Research & Development
Website
www.oncolys.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Oncolys BioPharma Inc. - timeline of key events
Oncolys BioPharma Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 185,750,000 | 396,754,000 | 1,180,000 | 28,797,000 | 121,303,000 | 178,313,000 | 229,139,000 | 168,549,000 | 1,303,844,000 | 314,179,000 | 642,494,000 | - | - | - |
| % Revenue Growth (YoY) | - | 113.6% | (99.7%) | 2340.4% | 321.2% | 47.0% | 28.5% | (26.4%) | 673.6% | (75.9%) | 104.5% | - | - | - |
| EBITDA (USD) | (145,624,925) | (140,954,000) | (648,323,000) | (815,193,000) | (934,811,000) | (845,947,000) | (1,077,227,000) | (1,245,854,000) | (508,354,000) | (1,669,762,000) | (1,379,543,000) | - | - | - |
| Operating Income (USD) | (145,624,925) | (140,954,000) | (665,462,000) | (827,744,000) | (951,575,000) | (861,311,000) | (1,078,389,000) | (1,247,563,000) | (511,463,000) | (1,674,652,000) | (1,454,554,000) | - | - | - |
| Operating Margin | (78.4%) | (35.5%) | (56395.1%) | (2874.4%) | (784.5%) | (483.0%) | (470.6%) | (740.2%) | (39.2%) | (533.0%) | (226.4%) | - | - | - |
| % EBITDA Margin | (78.4%) | (35.5%) | (54942.6%) | (2830.8%) | (770.6%) | (474.4%) | (470.1%) | (739.2%) | (39.0%) | (531.5%) | (214.7%) | - | - | - |
| NET Income (USD) | 14,989,277 | (102,829,000) | (635,553,000) | (738,999,000) | (857,290,000) | (931,397,000) | (1,090,703,000) | (1,233,846,000) | (912,346,000) | (2,095,087,000) | (1,615,439,000) | - | - | - |
| % Net Margin | 8.1% | (25.9%) | (53860.4%) | (2566.2%) | (706.7%) | (522.3%) | (476.0%) | (732.0%) | (70.0%) | (666.8%) | (251.4%) | - | - | - |
Oncolys BioPharma Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.